Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
275
Millions of yen (improvement in operating loss)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateOperating profit-17.1%
基準 1,605Target1,330million
Net income for the current fiscal year-16.9%
基準 1,625Target1,350million
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous planForecast for the fiscal year ended March 2026: business expenses 1,500, operating profit △1,500, net income △1,512 → Actual results for the fiscal year ended March 2026: business expenses 1,605, operating profit △1,605, net income △1,625（Business expenses 107%, operating profit 107%, net income 107% (progress against forecast)）0.0%Calculated from the two disclosed figures
Investment amount by sectorField Clinical Development / Amount Not disclosed, Field Strengthening the Development Structure / Amount Not disclosed
Key initiatives
01Advance clinical trials
02Conduct additional analyses and maximize value
03Regulatory approval, commercialization and partnering
04Continue discussions with the FDA
05Conduct additional and subgroup analyses
06Advance development of venetoclax combination therapy
07Advance strategic partnering
08DFP-10917 plus venetoclax combination therapy
09DFP-14323
10DFP-14927
11DFP-17729
Plan assumptionsAlthough milestone revenue may be secured, no revenue is included at this time due to uncertainty regarding the timing of negotiations and development progress.
Non-financial targetsIndicator Overall response rate (ORR) for DFP-10917 plus venetoclax combination therapy / Target value 50% in the Phase 1 part and 53% in the Phase 2 part (achieving the target ORR) / Timing As of May 2026
Size of the Target MarketSubject Acute myeloid leukemia (AML) / Scale Approximately 100,000 worldwide and approximately 8,800 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research), Cancer Statistics, 2026 (United States), and other sources, Subject Relapsed/refractory AML (United States) / Scale Approximately 11,500 patients eligible for treatment; an estimated 50% of patients with the disease are relapsed/refractory / Source Not disclosed, Subject Lung cancer / Scale Approximately 1.8 million worldwide and approximately 75,700 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources, Subject Pancreatic cancer / Scale Approximately 505,000 worldwide and approximately 41,500 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources, Subject Biliary tract cancer / Scale Approximately 200,000 worldwide and approximately 17,200 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources, Subject Stomach cancer / Scale Approximately 1 million worldwide and approximately 104,000 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources
Risks identified by the company
Management of R&D risks
Ensuring business continuity
Uncertainty regarding development progress
Uncertainty regarding the timing of negotiations
Reason for revision or withdrawal
Although milestone revenue may be secured, the plan does not include revenue at this time due to uncertainty regarding the timing of negotiations and development progress. Business expenses are expected to decline as R&D expenses decrease through efficiency gains following the completion of certain clinical trials, although investment in key pipelines will continue.
| Item | Details |
|---|---|
| Plan name | Business Plan (Forecast for the Fiscal Year Ending March 2027) |
| Plan period | Fiscal year ending March 2027 |
| Progress against the plan | Annual update |
| Operating profit target | △1,605 → △1,330（83%） |
| Net income target | △1,625 → △1,350（83%） |
| Investment amount by sector | Field Clinical Development / Amount Not disclosed, Field Strengthening the Development Structure / Amount Not disclosed |
| Non-financial targets | Indicator Overall response rate (ORR) for DFP-10917 plus venetoclax combination therapy / Target value 50% in the Phase 1 part and 53% in the Phase 2 part (achieving the target ORR) / Timing As of May 2026 |
| Plan assumptions | Although milestone revenue may be secured, no revenue is included at this time due to uncertainty regarding the timing of negotiations and development progress. |
| Key initiatives | Advance clinical trials, Conduct additional analyses and maximize value, Regulatory approval, commercialization and partnering, Continue discussions with the FDA, Conduct additional and subgroup analyses, Advance development of venetoclax combination therapy, Advance strategic partnering, DFP-10917 plus venetoclax combination therapy, DFP-14323, DFP-14927, DFP-17729 |
| Results under the previous plan | Forecast for the fiscal year ended March 2026: business expenses 1,500, operating profit △1,500, net income △1,512 → Actual results for the fiscal year ended March 2026: business expenses 1,605, operating profit △1,605, net income △1,625（Business expenses 107%, operating profit 107%, net income 107% (progress against forecast)） |
| Reason for revision or withdrawal | Although milestone revenue may be secured, the plan does not include revenue at this time due to uncertainty regarding the timing of negotiations and development progress. Business expenses are expected to decline as R&D expenses decrease through efficiency gains following the completion of certain clinical trials, although investment in key pipelines will continue. |
| Size of the Target Market | Subject Acute myeloid leukemia (AML) / Scale Approximately 100,000 worldwide and approximately 8,800 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research), Cancer Statistics, 2026 (United States), and other sources, Subject Relapsed/refractory AML (United States) / Scale Approximately 11,500 patients eligible for treatment; an estimated 50% of patients with the disease are relapsed/refractory / Source Not disclosed, Subject Lung cancer / Scale Approximately 1.8 million worldwide and approximately 75,700 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources, Subject Pancreatic cancer / Scale Approximately 505,000 worldwide and approximately 41,500 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources, Subject Biliary tract cancer / Scale Approximately 200,000 worldwide and approximately 17,200 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources, Subject Stomach cancer / Scale Approximately 1 million worldwide and approximately 104,000 in Japan (estimated annual number of patients) / Source Prepared by the Company based on Cancer Statistics 2026 (Japan Foundation for the Promotion of Cancer Research) and other sources |
| Risks identified | Management of R&D risks, Ensuring business continuity, Uncertainty regarding development progress, Uncertainty regarding the timing of negotiations |
| Publication date | 22 June 2026 |
Items this document does not state (11)
Sales TargetOperating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although milestone revenue may be secured, it is not included at this time due to uncertainty regarding the timing of negotiations and development progress. For business expenses, the Company expects R&D expenses to decrease through efficiency gains following the completion of certain clinical trials, while continuing to invest in key pipelines.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.